Tenofovir disoproxil fumarate treatment in HbeAg-positive patients

Basit Öğe Kaydı
dc.contributor.authorAyaz C.
dc.contributor.authorÇelen M.K.
dc.contributor.authorDal T.
dc.contributor.authorDeveci Ö.
dc.contributor.authorBayan K.
dc.contributor.authorMert D.
dc.contributor.authorOruç E.
dc.date.accessioned2024-04-24T18:43:46Z
dc.date.available2024-04-24T18:43:46Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractTenofovir disoproxil fumarate (Tenofovir DF) is a nucleotide analogue. This multicentre study reports retrospectively the long-term efficacy and safety data with tenofovir DF treatment in nucleosid(t)e-naive, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. Thirty-one patients (11 females, 20 males) received 245 mg tenofovir DF per diem. All patients’ initial serum hepatitis B virus (HBV) DNA levels were over 2,000 IU/ml. Serum alanine aminotransferase (ALT) levels, HBeAg, hepatitis B e antibodies (anti-HBe), hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (Anti-HBs), HBV DNA, creatinine and urea levels were evaluated at baseline, and at weeks 12, 24, 48 and 96 during therapy. Thirtyone patients completed 96 weeks of treatment. Mean age was 37.6±9.4 years. The initial mean value of ALT was 79±39.9 IU/L. At baseline, mean of fibrosis (Ishak) of liver biopsies was 2.3±0.7. Two of the patients (5.9%) achieved HBV DNA<300 copy at week 12 of treatment and 97.1% at week 96. HBeAg loss was observed in 6.7% of patients. At week 96, HBsAg loss was not observed in any of the patients. Mean ALT at week 48 was 32.7 U/L, at week 96 32.6 U/L. Renal safety was good. Creatinine remained stable. Tenofovir DF was well tolerated and produced potent, continuous viral suppression with increasing HBeAg loss. © 2015, EDIMES Edizioni Medico Scientifiche. All rights reserved.en_US
dc.identifier.endpage35en_US
dc.identifier.issn1124-9390
dc.identifier.issue1en_US
dc.identifier.pmid25819048en_US
dc.identifier.scopus2-s2.0-84926319074en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://hdl.handle.net/11468/24363
dc.identifier.volume23en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherEDIMES Edizioni Medico Scientificheen_US
dc.relation.ispartofInfezioni in Medicinaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHbeag-Positive Chronic Hepatitis B Patientsen_US
dc.subjectNucleosid(T)E-Naiveen_US
dc.subjectTenofovir Disoproxil Fumarate (Tenofovir Df)en_US
dc.titleTenofovir disoproxil fumarate treatment in HbeAg-positive patientsen_US
dc.title.alternativeTrattamento con tenofovir disoproxil fumarato in pazienti HbeAg-positivien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu